Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMB-003 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| HMB-003 | EXPERIMENTAL | Participants will be administered a single dose of HMB-003 at an escalating dose level according to the assigned cohort. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose |
| Name | Type | Description |
|---|---|---|
| HMB-003 | DRUG | HMB-003 will be administered subcutaneously as a single dose |
| Placebo | DRUG | Placebo will be administered subcutaneously as a single dose of placebo. |
Inclusion Criteria: * Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent. * Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG. Exclusion Criteria: * Participant has a history of clinically...
HMB-003 is an investigational small molecule developed by Hemab Therapeutics Holdings, Inc. It is designed to target plasmin and is currently in Phase 1 clinical development. The specific patient populations it may eventually treat have not been publicly disclosed.
HMB-003 targets plasmin. Plasmin is an enzyme involved in breaking down blood clots and in other proteolytic processes. By acting on plasmin, HMB-003 is being studied as a small molecule therapeutic, though its intended disease indications have not been disclosed.
HMB-003 is being developed by Hemab Therapeutics Holdings, Inc., which trades under the ticker COAG. The company is running the first-in-human study of the compound in the United States.
HMB-003 is in Phase 1 development. It is investigational and has not been approved by the FDA. The ongoing first-in-human trial is a Phase 1 study evaluating safety, pharmacokinetics, and pharmacodynamics in healthy adult volunteers.
HMB-003 is being studied in one active clinical trial, NCT07798505, titled a first-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of HMB-003 in healthy volunteers. The trial is currently recruiting, is placebo-controlled and double-blind, and plans to enroll 40 participants in the United States.
The Phase 1 trial of HMB-003, NCT07798505, enrolls healthy adult volunteers age 18 years and older, with no restriction by sex. It is a randomized, double-blind, placebo-controlled first-in-human study of 40 participants conducted in the United States.